Introduction
Approximately one-third of all intracellular proteins in mammalian cells are phosphorylated; this is a fundamental regulatory process catalyzed by protein kinases. Most cellular protein phosphorylation occurs on serine and threonine residues with tyrosine phosphorylation accounting for just 0.01 ± 0.05% of total protein phosphorylation (Hunter and Sefton, 1980) . Dephosphorylation of these residues is catalyzed by two major protein phosphatase families: phosphoserine/phosphothreonine speci®c protein phosphatases (PPases; e.g., PP1 and PP2A) and protein-tyrosine phosphatases (PTPases; e.g., PTP1B), which include the dual speci®city protein phosphatases (DSPases; e.g., VHR and Cdc25) that not only dephosphorylate phosphotyrosine but also phosphothreonine and phosphoserine on the same protein substrate.
The PTPases have similar conserved structural elements: a phosphate-binding loop, which contains the signature motif C(X) 5 R in a catalytic crevice between a b strand and a helix, and frequently a general acid on a surface loop (Cohn, 1989; Zhang et al., 1994) . In contrast, there are no similarities between the PPase and PTPase catalytic domains (Charbonneau et al., 1989; Cohn, 1989) . This is manifest in the dierent mechanisms of catalysis: while the PPases require metal ions and eect catalysis by direct attack of an activated water molecule at the phosphorous ion of the substrate (Barford, 1996) , the PTPases proceed via a covalent phosphocysteine intermediate (Zhang, 1997) . The macromolecular structural organization of the enzymes also diers: while the PPases exist in vivo as holoenzymes with multiple subunits; the PTPases are monomers containing a catalytic domain of up to 250 residues¯anked by amino or carboxyl terminal extensions with targeting or regulatory functions.
The importance of tyrosine phosphorylation in cellular regulation is revealed by its role in a wide range of cellular pathways. For example, tyrosine phosphorylation is a key reaction in the initiation and propagation of insulin action (Myers and White, 1996; White and Kahn, 1994) . Thus, PTP1B (Ahmad et al., 1995; Kenner et al., 1996; Kole et al., 1996) , LAR (Kulas et al., 1995; Zhang et al., 1996) and PTBa (Lammers et al., 1997; Moller et al., 1995) have been implicated as negative regulators of insulin receptor signaling. Consequently, protein phosphatase inhibitors may have use in the treatment of diabetes and obesity. Other PTPases have been associated with Xlinked recessive myotubular myopathy, a congenital muscle disorder (Kioschis et al., 1996) and in Lafora's disease, an autosomal recessive form of progressive myoclonus epilepsy characterized by seizures and cumulative neurological deterioration (Minassian et al., 1999) .
The mitogen (MAPK) and stress activated protein kinase (SAPK) signaling pathways, which control cellular proliferation, dierentiation, development, in¯ammatory responses and apoptosis, are regulated by both kinases and phosphatases. Examples of such phosphatases are the DSPases VHR, which terminate the catalytic activity of the extracellular regulated kinases (ERKs) (Todd et al., 1999) and MKP-5, which inactivates p38 and SAPK/JNK (Tanoue et al., 1999) .
Phosphatases may also represent novel targets for the development of antibiotics. The pathogenic bacterium Yersinia encodes a PTPase essential for its virulence (Bolin and Wolf-Watz, 1988) . Yersinia pestis was the pathogen responsible for the Bubonic Plague or Black Death (Butler, 1985) , which is predicted to have killed 200 million during human history (Brubaker, 1991) . The bacterial pathogen Salmonella typhimurium causes typhoid fever and food poisoning; it secretes PTPases that are required for its full display of virulence (Kaniga et al., 1996) . PTPase activity has also been detected in parasites such as Leishmania donovani (Cool and Blum, 1993) , Trypanosoma brucei and Trypanosoma cruzi (Bakalara et al., 1995a,b) , although it is less clear if these activities are important for their pathogenesis.
Cyclin-dependent protein phosphatases and cancer
One hallmark of oncogenic transformation is the deregulation of cell cycle control. Phosphorylation is an important regulatory mechanism for the cyclin dependent kinases (Cdk)/cyclin complexes that drive the cell cycle. Inhibitory phosphorylation on Thr and Tyr located in the glycine-rich ATP anchor motif of cdks results in inactivation (Figure 1) . The DSPase Cdc25 re-activates cdks via dephosphorylation of the inhibitory Thr and Tyr residues (Gautier et al., 1991) . There are three mammalian Cdc25 proteins, which dephosphorylate cdks at distinct phases of the cell cycle: Cdc25A acts on cdk2 and cdk4 in G1/S (Jinno et al., 1994) , and Cdc25B and C on cdk1 in G2/M (Lammer et al., 1998; Strausfeld et al., 1991) . In addition to their essential role in controlling these cell cycle checkpoints, Cdc25s are attractive targets for new therapeutics because: (a) they have a structure that is distinct from other PTPases; (b) they cooperate with other oncogenes in oncogenic transformation (Galaktionov et al., 1995b) ; (c) their expression is potentially controlled by at least two oncogenes, namely raf1 and c-myc (Galaktionov et al., 1995a (Galaktionov et al., , 1996 Xia et al., 1999) and, (d) they are overexpressed in many human tumors. Thus, Cdc25A and B are found overexpressed in non-Hodkin's (Hernandez et al., 1998 (Hernandez et al., , 2000 , head and neck (Gasparotto et al., 1997) , colon (Dixon et al., 1998) ; (Galaktionov et al., 1995b) , gastric (Kudo et al., 1997) and non-small cell lung (Wu et al., 1998) cancers. Elevated expression is associated with poor prognosis in some cancers (Galaktionov et al., 1995b; Hernandez et al., 1998 Hernandez et al., , 2000 Kudo et al., 1997) .
Regulation and structure of Cdc25
Amino acid sequence alignment of the three mammalian Cdc25 proteins reveals two general domains: the Cterminus, which comprises approximately one-third of the protein, is highly conserved and contains the catalytic activity; and the N-terminus, which has a regulatory role and is quite variable. The expression and activity of the Cdc25s are is regulated at multiple levels. For example, the expression of Cdc25B protein peaks in late S and G2 phase, when it is thought to be active (Garner-Hamrick and Fisher, 1998) . In addition, hyperphosphorylation of the N-terminus of Cdc25B regulates its ability to dephosphorylate cyclin B1/cdk1 (Gabrielli et al., 1997) . Excellent reviews on Cdc25 and regulation of its expression appear elsewhere (Draetta and Eckstein, 1997; Nilsson and Homann, 2000) . Both the expression and subcellular location of Cdc25 are aected by DNA integrity. Thus, DNA damage induces a ubiquitin-and proteasome-dependent degradation of Cdc25A (Bernardi et al., 2000; Mailand et al., 2000) , resulting in arrest at the G1/S cell cycle checkpoint. DNA damage also actives the chk1 pathway, leading to phosphorylation of Cdc25C on Ser-216, binding to a 14-3-3 isoform, sequestration in the cytoplasm and physical separation from its substrate (Figure 1 ) (Lopez-Girona et al., 1999; Peng et al., 1997) . This unique form of enzyme-substrate subcellular separation has also been proposed as a regulatory mechanism for Cdc25B (Davezac et al., 2000) .
The crystal structures of the catalytic domains of Cdc25A and B but not Cdc25C have been resolved. The active-site loop of Cdc25A showed similarity to the PTPases and this was shallow compared to other PTPases (Fauman et al., 1998) . The catalytic site comprised a small a/b domain with a central ®ve-stranded parallel b sheet with three helices below and two above (Fauman et al., 1998) . The overall structure and folding of the Cdc25B catalytic domain was similar to that of Cdc25A, although the Cdc25B domain was able to bind sulfate or other oxyanions in the catalytic site whereas the Cdc25A domain was unable to bind oxyanions (Reynolds et al., 1999) . In addition, there is a major dierence between the Cdc25A and Cdc25B crystal structures at their Ctermini. In Cdc25B the ®nal C-terminal residues lie along the primary protein molecule producing a cleft extending from the catalytic site. In contrast, the analogous C-terminal region in Cdc25A extends away from the main body of the protein and is disordered (Reynolds et al., 1999) . A second cysteine-containing cleft has been identi®ed in the Cdc25B structure that could be important for catalysis and, thus, as a region for small molecule disruption.
Small molecule inhibitors of Cdc25
Because of the apparent role of Cdc25 in neoplasia and the dierences between the catalytic domains of Cdc25 and other PTP/DSPases, there has been considerable interest in identifying speci®c Cdc25 inhibitors. The most common in vitro assays used to probe for potential small molecule inhibitors of Cdc25 enzyme activity involve recombinant, epitope-tagged Cdc25 that can be readily puri®ed and synthetic substrates, such as o-methyl¯uorescein phosphate (OMFP) Figure 1 Post-translational and spatial regulation of Cdc25C. The kinases, wee1 and myt1, inactive cdk1 by phosphorylating Thr-14 and Tyr-15. Dephosphorylation of cdk1 by nuclear Cdc25C activates the kinase. The chk1 pathway is activated by DNA damage leading to Cdc25C phosphorylation on Ser-216 and cytoplasmic sequestration due to 14-3-3 protein binding (Ducruet et al., 2000) ;¯uorescein diphosphate (FDP) (Rice et al., 1997) or; p-nitrophenyl phosphate (pNPP) (Koufaki et al., 1996) . The choice of substrate, however, can aect the enzyme kinetics, as can the domains of the enzyme used. Thus, truncation of either the amino or carboxyl terminus can markedly alter the kinetic properties of the enzyme. The phosphorylation status of Cdc25 is also important (Draetta and Eckstein, 1997) . Small molecular weight surrogate substrates are popular as substitutes for the more physiological cdk substrates, because cdks need to be isolated, phosphorylated and bound to cyclins. Unfortunately, small phosphopeptides modeled around the known cdk dephosphorylation region are poor substrates for Cdc25 and, thus, are seldom used (Cans et al., 1999) . Consequently, it is highly desirable to validate any inhibition seen with a nonprotein substrate in vitro with a cellular or in vivo observation especially because the requisite catalytic acid may actually be on the protein substrate (Chen et al., 2000) .
Several metal anions, most notably vanadate, are well-established, nonspeci®c inhibitors of the PTPase family, including Cdc25. Additional and sometimes more potent or selective Cdc25 inhibitors have emerged from studies of natural products (Eckstein, 2000) and several of these are illustrated in Figure 2 . A deep-water sponge from the Ircinia genus produces sul®rcin, which is a non-speci®c phosphatase inhibitor originally identi®ed as an antifungal agent (Cebula et al., 1997) . Sul®rcin has been used as a basic pharmacophore for the development of a small analog library with reduced structural and stereochemical complexity. In this series Cdc25A inhibition seemed to depend on the presence of a long aliphatic side chain and not on the sulfate moiety, which could be readily replaced with malonate without any appreciable loss in activity (Cebula et al., 1997) . Another marine sponge product, dysidiolide, was initially found to inhibit Cdc25A activity in vitro (Gunsakera et al., 1996) although subsequent de novo synthesis and reanalysis indicated that pure dysidiolide either has much less or no Cdc25 inhibitory activity . Presumably the anti-Cdc25 activity found in the original dysidiolide preparation was an unidenti®ed contaminant in the extract. Nonetheless, using dysidiolide as a pharmacophore, Takahashi et al. (2000) and Peng et al. (1998) synthesized compounds that mimicked substructures of dysidiolide. Pyrolysis of a cholesteryl acetate derivative produced Compound 7, which inhibited Cdc25A activity in the low mM range (Peng et al., 1998) . Several derivatives of Compound 7 were developed in an eort to produce a simpler inhibitor structure. Compound 15, a dithiocarboniccarboxylic acid derivative of cholestanol, was slightly more potent that the parental compound. Compound 15, like other compounds in this series, exhibited growth inhibitory activity against human cancer cell lines (Peng et al., 2000) . Analogs of vitamin D 3 , namely Compound 3b, possess Cdc25A-inhibitory activity in vitro and cause G1 arrest in HL60 cells, as expected of Cdc25A inhibitors .
Quinones also have been found to have activity against Cdc25 although, like almost all of the described compounds, little is known about their selectivity against other PTPases or even against other Cdc25 isoforms in vitro or within cells. Thus, the orthoquinone nocardione A inhibited Cdc25B phosphatase activity in vitro with an IC 50 of 17 mM (Otani et al., 2000) . In addition to its anti-Cdc25 activity, nocardione A has antifungal activity and is cytotoxic to HeLa cervical and SBC-5 non-small cell lung carcinomas (Otani et al., 2000) . Dnacins, which are benzoquinoid antibiotics with antitumor activity, inhibit Cdc25B non-competitively (Horiguchi et al., 1994) , although they also cause direct DNA damage through the generation of superoxide radicals (Horiguchi et al., 1994) . Naphthoquinones based on menadione or vitamin K 3 also inhibit Cdc25 phosphatases. Menadione was originally investigated, because it was known to have a broad range of antitumor activity, it aected the phosphorylation status and activity of tyrosine phosphatases, and it resembled mechanism-based phosphatase inhibitors (Ham et al., 1997) . Ham et al. demonstrated that menadione could irreversibly inhibit Cdc25A activity and compete with a known active site Cdc25 inhibitor, suggesting that its inhibition was due to covalent modi®cation of the active site (Ham et al., 1997) . Cellular studies with a vitamin K analog, Compound 11, indicate blockage of cell cycle progression at the G1/S transition, an increase in cdk2 phosphorylation and a concomitant decrease in cdk2 activity, consistent with inhibition of Cdc25A (Ham et al., 1998) . Another synthetic vitamin K analog, Compound 5, was independently identi®ed as a partial-competitive inhibitor of Cdc25 activity . Interestingly, Compound 5 causes a timedependent, irreversible inhibition of Cdc25 . Consistent with inhibition of cellular Cdc25A, B and C, Compound 5 increases the tyrosine phosphorylation of cdk2 and cdk4, decreases Rb phosphorylation, and produces profound G1 and G2/ M phase cell cycle arrests .
Both quinolines and isoquinolines have been reported to inhibit Cdc25 (El-Subbagh et al., 1999; Fritzen, et al., 2000) . We have re-synthesized both the quinoline-3-carboxylate and the naphthyridine-3-carboxylate, which were reported to have anti-Cdc25 activity (El-Subbagh et al., 1999) but were unable to demonstrate inhibition with our assay conditions (Rice et al., 1997; unpublished results) . A broad screening project allowed Fritzen et al. (2000) to identify isoquinolines with weak in vitro inhibitory activity against Cdc25B. They used a solid phase, combinatorial, synthetic approach to generate several inhibitors of Cdc25B including Compound 12 (Figure 2) , which had an IC 50 of 15 mM (Fritzen et al., 2000) . Although little has been reported about their speci®city, these tetrahydroisoquiolines might be a useful platform for future inhibitor design.
Natural products have also been used in the design of pharmacophore platforms for combinatorial synthetic approaches (Rice et al., 1997) . Thus, SC-aad9 is a competitive inhibitor of all 3 human Cdc25 isoforms in vitro with low mM K i values (Rice et al., 1997) . SCaad9 also inhibits cell cycle progression at both the G1 and G2/M phases in synchronized murine mammary carcinoma cells, causes enhanced tyrosine phosphorylation of cdk1, cdk2 and cdk4 and, decreases cdk4 kinase activity (Tamura et al., 1999) . A limited structureactivity study indicated the critical importance of a lipophilic nonyl-residue on SC-aad9 presumably due to interactions with a conserved hydrophobic region adjacent to the catalytic site. Anity for this hydrophobic region may account for the observed inhibition of Cdc25A in vitro with Compound 11, an N-methylmorpholino derivative of alkylphosphoether lipids (Figure 2 ; Koufaki et al., 1996) . These phosphoether lipids have antitumor activity against human xenografts (Koufaki et al., 1996) . Rigidifying the SC-aad9 pharmacophore yielded FY21-aa09, which is slightly more potent as an inhibitor of Cdc25 and has improved selectivity for the Cdc25 class of phosphatases (Ducruet et al., 2000) . Consistent with its antiphosphatase activity, FY21-aa09 inhibits MCF-7 and MDA-MB-231 breast cancer cell proliferation in vitro and causes cell cycle arrest at the G2/M transition (Ducruet et al., 2000) .
To explore the active site of Cdc25, Bergnes et al. (1999) designed a group of mechanism-based inhibitors using a four component Ugi reaction. One diamide, Compound 13, is the ®rst submicromolar inhibitor of Cdc25 reported to date and has a seven-and 120-fold selectivity for Cdc25A compared with VHR and PTP1B, respectively (Bergnes et al., 1999) . Surprisingly, in the context of the Ugi products, the phosphate moiety is not essential for inhibition. This ®nding is reconciled by the inhibitory kinetics: these compounds are noncompetitive inhibitors suggesting that they do not directly interact with the active site of the enzyme (Bergnes et al., 1999) .
While DNA damage causes the redistribution and a presumptive inactivation of Cdc25C, little is known about small molecules that might alter the subcellular Figure 2 Chemical structures of representative published inhibitors of Cdc25. In vitro IC 50 values and the Cdc25 isoform are indicated distribution of Cdc25A, B or C. The DNA topoisomerase II inhibitor and DNA damaging agent, etoposide, inhibited nuclear localization of Cdc25B in S phase, possibly by invoking a sequestration cascade (Woo et al., 1999) . These studies suggest it may be possible to identify reagents that selectively aect the subcellular distribution of dierent Cdc25 phosphatases in combination with agents causing DNA damage. These would be valuable tools to interrogate the functional role of Cdc25 sequestration.
Conclusions
Cdc25 phosphatases have a vital role in cell proliferation and checkpoint control. There is increasing evidence that aberrant Cdc25 functionality is important in oncogenesis. Recent crystal structures of the catalytic region of Cdc25 indicate their unique topology and suggest selective active site inhibitors of these enzymes may be approachable. Although several inhibitors have been identi®ed, their potency and speci®city are quite limited. The intracellular spatial modulation of Cdc25 provides an additional approach to modify the activity of these phosphatases.
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